WNT3A

Summary

WNT3A (Wnt family member 3A, HGNC:15983) is a protein-coding gene on chromosome 1q42.13, encoding Protein Wnt-3a (P56704). Ligand for members of the frizzled family of seven transmembrane receptors.

The WNT gene family consists of structurally related genes which encode secreted signaling proteins. These proteins have been implicated in oncogenesis and in several developmental processes, including regulation of cell fate and patterning during embryogenesis. This gene is a member of the WNT gene family. It encodes a protein which shows 96% amino acid identity to mouse Wnt3A protein, and 84% to human WNT3 protein, another WNT gene product. This gene is clustered with WNT14 gene, another family member, in chromosome 1q42 region.

Source: NCBI Gene 89780 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 182 total
• Phenotypes (HPO): 6
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_033131

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15983
Approved symbol	WNT3A
Name	Wnt family member 3A
Location	1q42.13
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000154342
Ensembl biotype	protein_coding
OMIM	606359
Entrez	89780

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000284523, ENST00000948304

RefSeq mRNA: 1 — MANE Select: NM_033131 NM_033131

CCDS: CCDS1564

Canonical transcript exons

ENST00000284523 — 4 exons

Exon	Start	End
ENSE00001015348	228050656	228050921
ENSE00001015349	228006998	228007199
ENSE00001015350	228058986	228061271
ENSE00002426379	228022667	228022908

Expression profiles

Bgee: expression breadth broad, 31 present calls, max score 86.63.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1885 / max 15.3457, expressed in 98 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
8906	0.1885	98

Top tissues by expression

128 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
placenta	UBERON:0001987	86.63	gold quality
right lung	UBERON:0002167	68.32	gold quality
upper lobe of left lung	UBERON:0008952	67.63	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	62.63	gold quality
lung	UBERON:0002048	62.14	gold quality
skin of leg	UBERON:0001511	60.02	gold quality
zone of skin	UBERON:0000014	59.64	gold quality
skin of abdomen	UBERON:0001416	59.15	gold quality
esophagus mucosa	UBERON:0002469	56.62	gold quality
lower esophagus mucosa	UBERON:0035834	55.95	gold quality
saliva-secreting gland	UBERON:0001044	53.59	gold quality
minor salivary gland	UBERON:0001830	53.16	gold quality
prostate gland	UBERON:0002367	53.02	gold quality
vagina	UBERON:0000996	48.41	gold quality
tonsil	UBERON:0002372	46.94	silver quality
bone marrow cell	CL:0002092	43.82	gold quality
colonic epithelium	UBERON:0000397	41.59	gold quality
esophagus	UBERON:0001043	40.36	gold quality
stromal cell of endometrium	CL:0002255	40.11	gold quality
sural nerve	UBERON:0015488	39.63	gold quality
adult mammalian kidney	UBERON:0000082	39.26	silver quality
fallopian tube	UBERON:0003889	37.40	gold quality
uterine cervix	UBERON:0000002	36.81	gold quality
bone marrow	UBERON:0002371	36.75	gold quality
right uterine tube	UBERON:0001302	36.63	silver quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
ectocervix	UBERON:0012249	36.40	gold quality
cortex of kidney	UBERON:0001225	35.59	gold quality
granulocyte	CL:0000094	35.55	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.43

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

4 targets.

Target	Regulation
AXIN2	Activation
CACNA1G	Activation
LEF1	Repression
TERT	Activation

Upstream regulators (CollecTRI, top): ERG, FOXQ1, HNF1B, HNF4A, KDM5B, MSGN1, MSX2, SMAD1, STAT3, TBX6

miRNA regulators (miRDB)

72 targeting WNT3A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-11181-3P	99.75	66.38	2205

Literature-anchored findings (GeneRIF, showing 40)

• Regulation of WNT3 and WNT3A mRNAs in human cancer cell lines NT2, MCF-7, and MKN45 (PMID:11788904)
• Clustered with WNT14 on 1q42. (PMID:11836627)
• wnt3a-beta catenin signaling regulates LEF-1 gene expression (PMID:12052822)
• CKI epsilon-dependent phosphorylation of Dvl enhances the formation of a complex of Dvl-1 with Frat-1 and this complex leads to the activation of Wnt-3a-induced accumulation of beta-catenin (PMID:12556519)
• These results suggest that Wnt responsiveness is a stage-specific phenomenon in B-cell development and that the morphological changes associated with Wnt signaling may play a role in the motility and metastatic potential of myeloma cells. (PMID:12629517)
• Results suggest that disabled-2 functions as a negative regulator of canonical Wnt signaling by stabilizing the beta-catenin degradation complex. (PMID:12805222)
• Wnt3a may stimulate a cellular phosphatase to dephosphorylate and activate CKIepsilon (PMID:14722104)
• Wnt/beta-catenin pathway activation by Wnt3a raised beta-catenin in monocytes & decreased migration thru a dermal microvascular endothelial cell layer. This was associated with specific monocyte adherence to endothelial cells after Wnt3a exposure. (PMID:16565323)
• BMP-2 antagonizes Wnt-3a signaling in osteoblast progenitors by promoting an interaction between Smad1 and Dvl-1 that restricts beta-catenin activation (PMID:16621789)
• ILK activity can modulate acute Wnt3a mediated beta-catenin phosphorylation, stabilization and nuclear activation in a PI3K-independent manner. (PMID:16799642)
• Wnt-LRP5 signalling may play a role in the adaptation of bone to mechanical load in humans, and may explain some gender-related differences in bone mass (PMID:17137849)
• Over-expression of the Wnt3a gene significantly enhances the ability of fibroblast feeder cells to support the undifferentiated growth of 3 different human embryonic stem cell lines. (PMID:17211448)
• Wnt3A/5A can function as mesenchymal regulatory factors by providing instructive cues for the recruitment, maintenance, and differentiation of mesenchymal stem cells. (PMID:17458904)
• Wnt3A treatment significantly activated human hepatic stellate cells, while this was inhibited in secreted frizzled-related protein 1 (sFRP1) overexpressing cells. (PMID:17544413)
• These results suggest that Wnt signaling crosstalk and functional antagonism with the LRP5 co-receptor are key signaling regulators of mesenchymal stem cells maintenance and differentiation. (PMID:17546602)
• Blockade of Wnt3a stimulation of IP(5) generation blocks beta-catenin accumulation (PMID:17595165)
• Results identify a novel feedback mechanism by which Wnt, including Wnt3a, negatively regulates LRP6 at the mRNA level. (PMID:17698587)
• These findings demonstrate a requirement of Wnt signaling for maintenance, proliferation, and survival of NP when cultured in neurosphere conditions. (PMID:17822920)
• Wnt3a markedly reduced the forskolin-induced expression of RANKL, a target gene of PTH/cAMP/PKA. (PMID:17990294)
• Our results suggest that Wnt/beta-catenin signaling plays important roles in human fetal skin development and homeostasis, which also provide new insights on the molecular mechanisms of oncogenesis in human epidermis. (PMID:18242164)
• bone marrow sera from 21 multiple myeloma patients significantly suppressed Wnt3a-induced OPG expression and enhanced RANKL expression in osteoblasts in a DKK1-dependent manner (PMID:18305214)
• effect of Wnt3a on bone disease and growth of multiple myeloma cells in vitro and in vivo (PMID:18344425)
• study demonstrated that Wnt3a & Wnt5a can promote proliferation of HEK293 cells & inhibit serum starvation-induced apoptosis, which implies Wnt3a & Wnt5a can maintain survival of HEK293 cells under stress (PMID:18462958)
• FGF antagonizes Wnt signaling by inhibiting Wnt-induced transcription and suggest that multiple mechanisms, including downregulation of TCFs and Wnt receptors, contribute to this effect. (PMID:18505824)
• glutamine synthetase has a role in control of glutamate signalling through Wnt3A and steroid pathways in osteoblastic cells (PMID:18555765)
• both Wnt5a and Wnt3a bound Ror2, only Wnt5a induced Ror2 homo-dimerization and tyrosine phosphorylation in U2OS human osteoblastic cells. (PMID:18615587)
• Wnt3a and Wnt5a have roles in inducing BMP-4 and 6 expression in prostate cancer osteoblast differentiation (PMID:18632632)
• essential role of Wnt3a in hepatocyte differentiation from hESCs; Wnt3a facilitates clonal plating of hESCs exhibiting functional hepatic differentiation (PMID:18719101)
• the frequent loss of stromal TGF-beta type II receptor expression in prostate cancer can relieve the paracrine suppression of Wnt3a expression (PMID:18724388)
• These findings suggest that WNT3A can mediate transcriptional changes in melanoma cells in a manner reminiscent of the known role of Wnt/beta-catenin signaling in normal melanocyte development. (PMID:19144919)
• Our study reveals an unappreciated role for noncanonical Wnt signaling in hESC specification that involves development of unique mesoderm precursors via morphogenic organization within human EBs. (PMID:19265664)
• The presence of WNT3a completely prevents normal adipocyte differentaiton. (PMID:19351711)
• Wnt3a induces canonical and non-canonical Wnt signaling in HUVECs, and stimulates their proliferation and migration. (PMID:19523451)
• Data show that mutated GPC3 lacking the GPI anchoring domain (sGPC3) significantly inhibited the in vivo growth, blocked Wnt signaling and Erk1/2 and Akt phosphorylation in tumors. (PMID:19816934)
• Wnt3A treatment greatly enhanced the effect of LRP6 on T-cell factor/lymphoid enhance factor luciferase activity in human mammary epithelial cells (PMID:19881541)
• Wnt-3A may activate canonical Wnt signaling and PI3K/AKT through distinct receptors. (PMID:19887570)
• Data demonstrate that the Wnt-beta-catenin signaling pathway is functional in platelets, and that a Wnt3a ligand inhibits platelet adhesion, activation, dense granule secretion, and aggregation. (PMID:19901330)
• Wnt/beta-catenin pathway activation might upregulate DIXDC1 through a post-translational mechanism by inhibiting the ubiquitin-mediated degradation of the DIXDC1 protein. (PMID:20085589)
• analysis of the frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6 (PMID:20093360)
• Loss of CYLD instigates tumor growth in human cylindromatosis through a mechanism in which hyperubiquitination of polymerized Dvl drives enhancement of Wnt3/beta-catenin responses. (PMID:20227366)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	wnt3a	ENSDARG00000058822
mus_musculus	Wnt3a	ENSMUSG00000009900
rattus_norvegicus	Wnt3a	ENSRNOG00000003039
drosophila_melanogaster	Wnt2	FBGN0004360
drosophila_melanogaster	Wnt5	FBGN0010194
drosophila_melanogaster	Wnt10	FBGN0031903
caenorhabditis_elegans		WBGENE00000857
caenorhabditis_elegans		WBGENE00000858
caenorhabditis_elegans	lin-44	WBGENE00003029

Paralogs (18): WNT16 (ENSG00000002745), WNT8A (ENSG00000061492), WNT8B (ENSG00000075290), WNT11 (ENSG00000085741), WNT2 (ENSG00000105989), WNT3 (ENSG00000108379), WNT5B (ENSG00000111186), WNT5A (ENSG00000114251), WNT6 (ENSG00000115596), WNT1 (ENSG00000125084), WNT2B (ENSG00000134245), WNT10A (ENSG00000135925), WNT9A (ENSG00000143816), WNT7A (ENSG00000154764), WNT9B (ENSG00000158955), WNT4 (ENSG00000162552), WNT10B (ENSG00000169884), WNT7B (ENSG00000188064)

Protein

Protein identifiers

Protein Wnt-3a — P56704 (reviewed: P56704)

All UniProt accessions (1): P56704

UniProt curated annotations — full annotation on UniProt →

Function. Ligand for members of the frizzled family of seven transmembrane receptors. Functions in the canonical Wnt signaling pathway that results in activation of transcription factors of the TCF/LEF family. Required for normal embryonic mesoderm development and formation of caudal somites. Required for normal morphogenesis of the developing neural tube. Mediates self-renewal of the stem cells at the bottom on intestinal crypts (in vitro).

Subunit / interactions. Forms a soluble 1:1 complex with AFM; this prevents oligomerization and is required for prolonged biological activity. The complex with AFM may represent the physiological form in body fluids. Homooligomer; disulfide-linked, leading to inactivation. Interacts with PORCN. Interacts with APCDD1 and WLS. Component of the Wnt-Fzd-LRP5-LRP6 signaling complex that contains a WNT protein, a FZD protein and LRP5 or LRP6. Interacts directly in the complex with LRP6. Interacts with glypican GPC3. Interacts with PKD1 (via extracellular domain). Interacts with FZD5.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Tissue specificity. Moderately expressed in placenta and at low levels in adult lung, spleen, and prostate.

Post-translational modifications. Palmitoleoylation by PORCN is required for efficient binding to frizzled receptors. Palmitoleoylation is required for proper trafficking to cell surface, vacuolar acidification is critical to release palmitoleoylated WNT3A from WLS in secretory vesicles. Depalmitoleoylated by NOTUM, leading to inhibit Wnt signaling pathway, possibly by promoting disulfide bond formation and oligomerization. Proteolytic processing by TIKI1 and TIKI2 promotes oxidation and formation of large disulfide-bond oligomers, leading to inactivation of WNT3A. Disulfide bonds have critical and distinct roles in secretion and activity. Loss of each conserved cysteine in WNT3A results in high molecular weight oxidized Wnt oligomers, which are formed through inter-Wnt disulfide bonding.

Similarity. Belongs to the Wnt family.

Isoforms (2)

UniProt ID	Names	Canonical?
P56704-1	1	yes
P56704-2	2

RefSeq proteins (1): NP_149122* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005817	Wnt	Family
IPR009141	Wnt3	Family
IPR018161	Wnt_CS	Conserved_site
IPR043158	Wnt_C	Homologous_superfamily

Pfam: PF00110

UniProt features (59 total): strand 18, helix 12, disulfide bond 11, mutagenesis site 7, turn 4, glycosylation site 2, signal peptide 1, chain 1, splice variant 1, site 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
7DRT	ELECTRON MICROSCOPY	2.2
7URD	ELECTRON MICROSCOPY	2.92
7URE	ELECTRON MICROSCOPY	3.19
8TZR	ELECTRON MICROSCOPY	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P56704-F1	88.62	0.77

Antibody-complex structures (SAbDab): 2 — 7URD, 7URE

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 26–27 (cleavage; by tiki1 and tiki2)

Post-translational modifications (1): 209

Disulfide bonds (11): 205–212, 281–312, 297–307, 311–351, 327–342, 329–339, 334–335, 77–88, 128–136, 138–155, 203–217

Glycosylation sites (2): 87, 298

Mutagenesis-validated functional residues (7):

Position	Phenotype
87	strongly reduced ability to stimulate wnt-responsive reporters; when associated with q-298.
209	abrogates wls binding.
209	complete loss of palmitoleoylation.
209	no effect on palmitoleoylation and secretion; the threonine can functionally replace the serine.
298	strongly reduced ability to stimulate wnt-responsive reporters; when associated with q-87.
334	no signaling activity despite the presence of significant amounts of secreted monomeric wnt3a, exhibits dominant negativ
335	no signaling activity despite the presence of significant amounts of secreted monomeric wnt3a, exhibits dominant negativ

Function

Pathways and Gene Ontology

Reactome pathways

11 pathways

ID	Pathway
R-HSA-201681	TCF dependent signaling in response to WNT
R-HSA-3238698	WNT ligand biogenesis and trafficking
R-HSA-373080	Class B/2 (Secretin family receptors)
R-HSA-3772470	Negative regulation of TCF-dependent signaling by WNT ligand antagonists
R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane
R-HSA-4641263	Regulation of FZD by ubiquitination
R-HSA-5340588	Signaling by RNF43 mutants
R-HSA-9793380	Formation of paraxial mesoderm
R-HSA-9832991	Formation of the posterior neural plate
R-HSA-9834899	Specification of the neural plate border
R-HSA-9856649	Transcriptional and post-translational regulation of MITF-M expression and activity

MSigDB gene sets: 490 (showing top): GOBP_SPINAL_CORD_DEVELOPMENT, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_HEPATOCYTE_PROLIFERATION, MODULE_92, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_REGULATION_OF_COLLATERAL_SPROUTING, GOBP_NEGATIVE_REGULATION_OF_NEURON_DIFFERENTIATION, GOBP_REGULATION_OF_SKELETAL_MUSCLE_TISSUE_DEVELOPMENT, GOBP_MUSCLE_TISSUE_DEVELOPMENT

GO Biological Process (81): osteoblast differentiation (GO:0001649), in utero embryonic development (GO:0001701), positive regulation of cytokine production (GO:0001819), heart looping (GO:0001947), positive regulation of receptor internalization (GO:0002092), transcription by RNA polymerase II (GO:0006366), axon guidance (GO:0007411), heart development (GO:0007507), intracellular protein localization (GO:0008104), COP9 signalosome assembly (GO:0010387), positive regulation of gene expression (GO:0010628), negative regulation of neuron projection development (GO:0010977), spinal cord association neuron differentiation (GO:0021527), hippocampus development (GO:0021766), cell proliferation in forebrain (GO:0021846), Wnt signaling pathway involved in forebrain neuroblast division (GO:0021874), dorsal/ventral neural tube patterning (GO:0021904), hemopoiesis (GO:0030097), neuron differentiation (GO:0030182), extracellular matrix organization (GO:0030198), mammary gland development (GO:0030879), positive regulation of B cell proliferation (GO:0030890), cell proliferation in midbrain (GO:0033278), non-canonical Wnt signaling pathway (GO:0035567), skeletal muscle cell differentiation (GO:0035914), post-anal tail morphogenesis (GO:0036342), synaptic vesicle recycling (GO:0036465), B cell proliferation (GO:0042100), inner ear morphogenesis (GO:0042472), cell fate commitment (GO:0045165), fat cell differentiation (GO:0045444), myoblast differentiation (GO:0045445), negative regulation of fat cell differentiation (GO:0045599), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), somatic stem cell division (GO:0048103), positive regulation of mesodermal cell fate specification (GO:0048337), paraxial mesodermal cell fate commitment (GO:0048343), positive regulation of skeletal muscle tissue development (GO:0048643), positive regulation of collateral sprouting in absence of injury (GO:0048697)

GO Molecular Function (9): transcription coactivator activity (GO:0003713), signaling receptor binding (GO:0005102), frizzled binding (GO:0005109), cytokine activity (GO:0005125), protein domain specific binding (GO:0019904), co-receptor binding (GO:0039706), identical protein binding (GO:0042802), receptor ligand activity (GO:0048018), protein binding (GO:0005515)

GO Cellular Component (13): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), endoplasmic reticulum lumen (GO:0005788), Golgi lumen (GO:0005796), plasma membrane (GO:0005886), cell surface (GO:0009986), endocytic vesicle membrane (GO:0030666), early endosome membrane (GO:0031901), extracellular exosome (GO:0070062), presynapse (GO:0098793), glutamatergic synapse (GO:0098978), Wnt-Frizzled-LRP5/6 complex (GO:1990851), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
TCF dependent signaling in response to WNT	3
Gastrulation	3
Signaling by WNT	2
GPCR ligand binding	1
Signaling by WNT in cancer	1
MITF-M-regulated melanocyte development	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	4
cellular anatomical structure	3
cell differentiation	2
intracellular organelle lumen	2
synapse	2
ossification	1
chordate embryonic development	1
cytokine production	1
regulation of cytokine production	1
positive regulation of gene expression	1
positive regulation of multicellular organismal process	1
embryonic heart tube morphogenesis	1
determination of heart left/right asymmetry	1
regulation of receptor internalization	1
receptor internalization	1
positive regulation of receptor-mediated endocytosis	1
DNA-templated transcription	1
axonogenesis	1
neuron projection guidance	1
animal organ development	1
circulatory system development	1
macromolecule localization	1
protein-containing complex assembly	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
regulation of neuron projection development	1
neuron projection development	1
negative regulation of cell projection organization	1
cell differentiation in spinal cord	1
dorsal spinal cord development	1
central nervous system neuron differentiation	1
pallium development	1
limbic system development	1
anatomical structure development	1
forebrain development	1
neural precursor cell proliferation	1
Wnt signaling pathway	1
forebrain neuroblast division	1
dorsal/ventral pattern formation	1

Protein interactions and networks

STRING

2818 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WNT3A	LRP6	O75581	998
WNT3A	LRP5	O75197	998
WNT3A	FZD1	Q9UP38	994
WNT3A	FZD2	Q14332	981
WNT3A	FZD8	Q9H461	954
WNT3A	CTNNB1	P35222	949
WNT3A	APCDD1	Q8J025	949
WNT3A	DVL1	O14640	928
WNT3A	AXIN1	O15169	927
WNT3A	RYK	P34925	925
WNT3A	DKK1	O94907	908
WNT3A	WIF1	Q9Y5W5	903
WNT3A	RSPO1	Q2MKA7	901
WNT3A	AXIN2	Q9Y2T1	887
WNT3A	FZD4	Q9ULV1	882

IntAct

28 interactions, top by confidence:

A	B	Type	Score
WNT3A	WLS	psi-mi:“MI:0915”(physical association)	0.780
LRP6	WNT3A	psi-mi:“MI:0407”(direct interaction)	0.770
WNT3A	LRP6	psi-mi:“MI:0915”(physical association)	0.770
WNT3	WNT3A	psi-mi:“MI:0914”(association)	0.640
FZD7	LRP6	psi-mi:“MI:0914”(association)	0.620
FZD5	tcdB	psi-mi:“MI:0915”(physical association)	0.610
WNT3A	CANX	psi-mi:“MI:0914”(association)	0.530
APCDD1	WNT3A	psi-mi:“MI:0915”(physical association)	0.520
TRABD2B	WNT3A	psi-mi:“MI:0194”(cleavage reaction)	0.520
FZD7	TRABD2B	psi-mi:“MI:0914”(association)	0.520
TRABD2B	FZD7	psi-mi:“MI:0914”(association)	0.520
WNT3A	FZD8	psi-mi:“MI:0915”(physical association)	0.500
FZD8	WNT3A	psi-mi:“MI:0914”(association)	0.500
NOTUM	WNT3A	psi-mi:“MI:0197”(deacetylation reaction)	0.440
FZD2	WNT3A	psi-mi:“MI:0407”(direct interaction)	0.440
WNT3A	AFM	psi-mi:“MI:0915”(physical association)	0.400
WNT3A	Fzd8	psi-mi:“MI:0915”(physical association)	0.400
WNT3A	MANBA	psi-mi:“MI:0914”(association)	0.350
WNT3A	LRP5	psi-mi:“MI:0914”(association)	0.350
SLC22A1	FNDC10	psi-mi:“MI:0914”(association)	0.350

BioGRID (57): CANX (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), WNT3 (Affinity Capture-MS), PPP2R1B (Affinity Capture-MS), PPP2R5D (Affinity Capture-MS), PPP2R5A (Affinity Capture-MS), PPP2R5B (Affinity Capture-MS), PPP2R5E (Affinity Capture-MS), FEM1B (Affinity Capture-MS), PPP2R2D (Affinity Capture-MS), TRAF2 (Affinity Capture-MS), WNT3 (Affinity Capture-MS), PPP2R5A (Affinity Capture-MS), PPP2R5B (Affinity Capture-MS), PPP2R5E (Affinity Capture-MS)

ESM2 similar proteins: A2AIR5, A5D8T8, A6QLN9, O18739, O35217, O35393, O54951, O75077, O75078, O75900, P27467, P28686, P42642, P49641, P56704, Q00961, Q01098, Q08DW9, Q14957, Q1LZB9, Q2TBM7, Q4V7F2, Q5EA46, Q5R890, Q642A6, Q6P988, Q6PCB0, Q6UXF7, Q7TNS7, Q8NCF0, Q8R2Z5, Q8TCU5, Q91XD7, Q96CW9, Q96FT7, Q96HD1, Q96N03, Q9BZ11, Q9ESM2, Q9ESM3

Diamond homologs: A0M8S1, A0M8T2, A1X153, A4D7S0, B2GUT4, O00755, O13267, O15978, O42122, O70283, P04426, P04628, P09544, P09615, P10108, P17553, P21551, P21552, P22724, P22725, P22726, P22727, P24257, P24383, P27467, P28047, P28465, P31285, P31286, P33945, P34888, P34889, P41221, P43446, P47793, P49337, P49338, P49339, P49340, P49893

SIGNOR signaling

26 interactions.

A	Effect	B	Mechanism
WNT3A	up-regulates	RYK	binding
WNT3A	“up-regulates activity”	LRP5	binding
WNT3A	“up-regulates activity”	LRP6	binding
WNT3A	“up-regulates activity”	FZD1	binding
WNT3A	“up-regulates activity”	FZD3	binding
WNT3A	“up-regulates activity”	DVL1
WNT3A	up-regulates	ALPL
DKK1	down-regulates	WNT3A
SOST	down-regulates	WNT3A
WNT3A	up-regulates	FZD2	binding
GPC4	up-regulates	WNT3A	binding
WNT3A	up-regulates	FZD8	binding
SOSTDC1	“down-regulates activity”	WNT3A
WNT3A	“up-regulates activity”	Frizzled	binding
PORCN	“up-regulates activity”	WNT3A	palmitoylation
WLS	“up-regulates activity”	WNT3A	relocalization
WNT3A	“up-regulates quantity by stabilization”	FBN1
ERG	“up-regulates quantity by expression”	WNT3A	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 18 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Class B/2 (Secretin family receptors)	5	79.3×	9e-08

GO biological processes:

GO term	Partners	Fold	FDR
canonical Wnt signaling pathway	7	71.5×	5e-10
Wnt signaling pathway	6	39.9×	4e-07
neuron differentiation	5	33.4×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

182 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	113
Likely benign	60
Benign	7

Top pathogenic / likely-pathogenic (0)

SpliceAI

1023 predictions. Top by Δscore:

Variant	Effect	Δscore
1:228022906:AAGG:A	donor_loss	1.0000
1:228022907:AGG:A	donor_loss	1.0000
1:228022908:GGTA:G	donor_loss	1.0000
1:228022909:GTAT:G	donor_loss	1.0000
1:228022910:T:G	donor_loss	1.0000
1:228050919:CAGG:C	donor_loss	1.0000
1:228050921:GGTA:G	donor_loss	1.0000
1:228050922:G:C	donor_loss	1.0000
1:228050923:T:A	donor_loss	1.0000
1:228007197:GTG:G	donor_gain	0.9900
1:228007200:GT:G	donor_loss	0.9900
1:228007202:G:GT	donor_loss	0.9900
1:228007204:G:GG	donor_gain	0.9900
1:228022661:CTGCA:C	acceptor_loss	0.9900
1:228022662:TGCA:T	acceptor_loss	0.9900
1:228022663:GCAG:G	acceptor_loss	0.9900
1:228022664:CAGG:C	acceptor_loss	0.9900
1:228022665:A:AG	acceptor_gain	0.9900
1:228022666:G:GG	acceptor_gain	0.9900
1:228050651:TACA:T	acceptor_loss	0.9900
1:228050654:A:AG	acceptor_gain	0.9900
1:228050655:G:GA	acceptor_gain	0.9900
1:228050655:GCT:G	acceptor_gain	0.9900
1:228007195:TGGTG:T	donor_gain	0.9800
1:228007196:GGTGG:G	donor_gain	0.9800
1:228007200:G:GG	donor_gain	0.9800
1:228007203:A:AG	donor_gain	0.9800
1:228016775:TGG:T	donor_gain	0.9800
1:228022666:GGTC:G	acceptor_gain	0.9800
1:228050651:TACAG:T	acceptor_gain	0.9800

AlphaMissense

2306 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:228022762:G:A	C56Y	1.000
1:228022824:T:A	C77S	1.000
1:228022825:G:C	C77S	1.000
1:228022826:C:G	C77W	1.000
1:228022851:T:A	W86R	1.000
1:228022851:T:C	W86R	1.000
1:228022853:G:C	W86C	1.000
1:228022853:G:T	W86C	1.000
1:228022858:G:A	C88Y	1.000
1:228022859:C:G	C88W	1.000
1:228050682:G:C	A114P	1.000
1:228050798:G:C	W152C	1.000
1:228050798:G:T	W152C	1.000
1:228050848:T:G	F169C	1.000
1:228050903:C:A	N187K	1.000
1:228050903:C:G	N187K	1.000
1:228050913:G:T	G191W	1.000
1:228059245:T:G	F280C	1.000
1:228059247:T:A	C281S	1.000
1:228059248:G:A	C281Y	1.000
1:228059248:G:C	C281S	1.000
1:228059295:T:A	C297S	1.000
1:228059296:G:C	C297S	1.000
1:228022719:T:A	C42S	0.999
1:228022720:G:C	C42S	0.999
1:228022761:T:A	C56S	0.999
1:228022761:T:C	C56R	0.999
1:228022762:G:C	C56S	0.999
1:228022763:C:G	C56W	0.999
1:228022800:G:C	G69R	0.999

dbSNP variants (sampled 300 via entrez): RS1000026843 (1:228013599 A>T), RS1000066759 (1:228008914 A>G), RS1000182727 (1:228030844 T>C), RS1000276301 (1:228019133 A>T), RS1000366662 (1:228059833 T>A,C,G), RS1000380136 (1:228024885 G>A), RS1000400741 (1:228029983 C>A), RS1000436733 (1:228053273 A>G), RS1000449178 (1:228018869 G>A), RS1000454573 (1:228037021 C>T), RS1000537972 (1:228008072 G>A), RS1000655760 (1:228008130 A>G), RS1000664638 (1:228058937 G>A,C), RS1000699529 (1:228058401 G>A), RS1000716586 (1:228023424 G>A)

Disease associations

OMIM: gene MIM:606359 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

6 total (6 of 6 shown, HPO-id order):

HPO	Term
HP:0000939	Osteoporosis
HP:0001288	Gait disturbance
HP:0002653	Bone pain
HP:0002757	Recurrent fractures
HP:0002808	Kyphosis
HP:0002953	Vertebral compression fracture

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004280_9	Diastolic blood pressure	2.000000e-16
GCST007930_8	Medication use (agents acting on the renin-angiotensin system)	3.000000e-10
GCST008362_97	Birth weight	2.000000e-09
GCST008839_18	Height	3.000000e-18
GCST90092003_2	Alcohol-related hepatocellular carcinoma	1.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0009931	Agents acting on the renin-angiotensin system use measurement
EFO:0004344	birth weight

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL1255137 (SINGLE PROTEIN), CHEMBL6066542 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,238 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL3188386	WNT-974	2	1,238

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

516 measured of 536 human assays (536 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(2-fluoro-5-methyl-4-(2-methylpyridin-4-yl)phenyl)acetamide	IC50	0.04 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-[5-(3-fluorophenyl)-2-pyridinyl]-2-[6-(2-methyl-4-pyridinyl)-3-pyridinyl]acetamide	IC50	0.06 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[4-(2-methyl-4-pyridinyl)phenyl]-N-(5-pyridin-3-yl-2-pyridinyl)acetamide	IC50	0.07 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[6-(2-methyl-4-pyridinyl)-3-pyridinyl]-N-(6-phenylpyridazin-3-yl)acetamide	IC50	0.08 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[3-methyl-4-(2-methyl-4-pyridinyl)phenyl]-N-(5-pyridin-2-yl-2-pyridinyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[4-pyridazin-4-yl-3-(trifluoromethyl)phenyl]-N-(5-pyridin-2-yl-2-pyridinyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(pyrazin-2-yl)pyridin-2-yl)-2-(4-(pyridazin-4-yl)-3-(trifluoromethyl)phenyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-[5-(3-fluorophenyl)-2-pyridinyl]-2-(4-pyridazin-4-ylphenyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[4-(2-methyl-4-pyridinyl)-3-(trifluoromethyl)phenyl]-N-(5-pyridin-2-yl-2-pyridinyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
Methyl 4-(6-(2-(4-(2-methylpyridin-4-yl)phenyl)acetamido)pyridin-3-yl)piperazine-1-carboxylate	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-(3-methyl-4-pyridazin-4-ylphenyl)-N-(5-pyrazin-2-yl-2-pyridinyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
methyl 4-[6-[[2-[5-methyl-6-(2-methyl-4-pyridinyl)-3-pyridinyl]acetyl]amino]-3-pyridinyl]piperazine-1-carboxylate	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
methyl 4-[6-[[2-[3-methyl-4-(2-methyl-4-pyridinyl)phenyl]acetyl]amino]-3-pyridinyl]piperazine-1-carboxylate	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-fluoro-4-(2-methylpyridin-4-yl)phenyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-[5-(4-acetylpiperazin-1-yl)-2-pyridinyl]-2-[3-chloro-4-(2-methyl-4-pyridinyl)phenyl]acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(4-(2-methylpyridin-4-yl)-3-(trifluoromethyl)phenyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[3-cyano-4-(2-methyl-4-pyridinyl)phenyl]-N-(6-phenyl-3-pyridinyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(4-(2-fluoropyridin-4-yl)phenyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[3-cyano-4-(2-methyl-4-pyridinyl)phenyl]-N-(5-pyrazin-2-yl-2-pyridinyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[3-cyano-4-(2-methyl-4-pyridinyl)phenyl]-N-(6-pyrazin-2-yl-3-pyridinyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-(3-cyano-4-(2-methylpyridin-4-yl)phenyl)-N-(5-(pyridazin-3-yl)pyridin-2-yl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-methoxy-4-(2-methylpyridin-4-yl)phenyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-chloro-2’-methyl-2,4’-bipyridin-5-yl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-[5-[(3S)-4-acetyl-3-methylpiperazin-1-yl]-2-pyridinyl]-2-[3-cyano-4-(2-methyl-4-pyridinyl)phenyl]acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
propan-2-yl 4-[6-[[2-[5-methyl-6-(2-methyl-4-pyridinyl)-3-pyridinyl]acetyl]amino]-3-pyridinyl]piperazine-1-carboxylate	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(2’-methyl-3-(trifluoromethyl)-2,4’-bipyridin-5-yl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(2’-fluoro-3-methyl-2,4’-bipyridin-5-yl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-(2’,3-difluoro-2,4’-bipyridin-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-cyano-4-(2-fluoropyridin-4-yl)phenyl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-(3-fluoro-4-(2-fluoropyridin-4-yl)phenyl)-N-(5-(pyridazin-3-yl)pyridin-2-yl)acetamide	IC50	0.1 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-[6-(3-fluorophenyl)-3-pyridinyl]-2-[4-pyridazin-4-yl-3-(trifluoromethyl)phenyl]acetamide	IC50	0.11 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-cyano-4-(2-methylpyridin-4-yl)phenyl)acetamide	IC50	0.11 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-(3-methyl-4-pyridazin-4-ylphenyl)-N-(5-pyridin-2-yl-2-pyridinyl)acetamide	IC50	0.12 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[4-(2-methyl-4-pyridinyl)-3-(trifluoromethyl)phenyl]-N-(5-pyrazin-2-yl-2-pyridinyl)acetamide	IC50	0.13 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-[5-(3-fluorophenyl)-2-pyridinyl]-2-[5-methyl-6-(2-methyl-4-pyridinyl)-3-pyridinyl]acetamide	IC50	0.13 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[4-(2-methyl-4-pyridinyl)phenyl]-N-(6-phenylpyridazin-3-yl)acetamide	IC50	0.14 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[4-(2-methyl-4-pyridinyl)phenyl]-N-(5-pyridazin-3-yl-2-pyridinyl)acetamide	IC50	0.15 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-[5-(3-fluorophenyl)-2-pyridinyl]-2-[4-(2-methyl-4-pyridinyl)-3-(trifluoromethyl)phenyl]acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-[6-(3-fluorophenyl)-3-pyridinyl]-2-[6-(2-methyl-4-pyridinyl)-3-pyridinyl]acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-pyridazin-3-yl-2-pyridinyl)-2-[4-pyridazin-4-yl-3-(trifluoromethyl)phenyl]acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(2,3’-bipyridin-6’-yl)-2-(2’,3-dimethyl-2,4’-bipyridin-5-yl)acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
tert-butyl 4-(6-(2-(4-(2-methylpyridin-4-yl)phenyl)acetamido)pyridin-3-yl)piperazine-1-carboxylate	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-methyl-4-(2-methylpyridin-4-yl)phenyl)acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
ethyl 4-[6-[[2-[3-methyl-2-(2-methyl-4-pyridinyl)-2H-pyran-5-yl]acetyl]amino]-3-pyridinyl]piperazine-1-carboxylate	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(4-(2-chloropyridin-4-yl)phenyl)acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-cyano-2’-methyl-2,4’-bipyridin-5-yl)acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-fluoro-2’-methyl-2,4’-bipyridin-5-yl)acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(4-(2-methylpyrimidin-4-yl)-3-(trifluoromethyl)phenyl)acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-(2’-fluoro-3-methyl-2,4’-bipyridin-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators
2-[4-(2-fluoro-4-pyridinyl)phenyl]-N-(5-pyrazin-2-yl-2-pyridinyl)acetamide	IC50	0.2 nM	US-10251893: N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators

ChEMBL bioactivities

850 potent at pChembl≥5 of 927 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.40	IC50	0.04	nM	CHEMBL5823795
10.22	IC50	0.06	nM	CHEMBL6039603
10.15	IC50	0.07	nM	CHEMBL5921303
10.10	IC50	0.08	nM	CHEMBL6033847
10.00	IC50	0.1	nM	CHEMBL5945646
10.00	IC50	0.1	nM	CHEMBL5937289
10.00	IC50	0.1	nM	CHEMBL6018741
10.00	IC50	0.1	nM	CHEMBL5914153
10.00	IC50	0.1	nM	CHEMBL6001502
10.00	IC50	0.1	nM	CHEMBL6029730
10.00	IC50	0.1	nM	CHEMBL5989592
10.00	IC50	0.1	nM	CHEMBL4532746
10.00	IC50	0.1	nM	CHEMBL5898705
10.00	IC50	0.1	nM	CHEMBL5889799
10.00	IC50	0.1	nM	CHEMBL5785948
10.00	IC50	0.1	nM	CHEMBL5955254
10.00	IC50	0.1	nM	CHEMBL5759987
10.00	IC50	0.1	nM	CHEMBL5815787
10.00	IC50	0.1	nM	CHEMBL5846874
10.00	IC50	0.1	nM	CHEMBL6042520
10.00	IC50	0.1	nM	CHEMBL5840741
10.00	IC50	0.1	nM	CHEMBL5968250
10.00	IC50	0.1	nM	CHEMBL5761075
10.00	IC50	0.1	nM	CHEMBL6056464
10.00	IC50	0.1	nM	CHEMBL6001723
10.00	IC50	0.1	nM	CHEMBL5760694
10.00	IC50	0.1	nM	CHEMBL4546441
10.00	IC50	0.1	nM	CHEMBL5801448
10.00	IC50	0.1	nM	CHEMBL5839562
10.00	IC50	0.1	nM	CHEMBL5810452
9.96	IC50	0.11	nM	CHEMBL6019535
9.96	IC50	0.11	nM	CHEMBL5822915
9.92	IC50	0.12	nM	CHEMBL6055708
9.89	IC50	0.13	nM	CHEMBL5995349
9.89	IC50	0.13	nM	CHEMBL6052903
9.85	IC50	0.14	nM	CHEMBL5874786
9.82	IC50	0.15	nM	CHEMBL5798889
9.70	IC50	0.2	nM	CHEMBL5904878
9.70	IC50	0.2	nM	CHEMBL5947565
9.70	IC50	0.2	nM	CHEMBL5910225
9.70	IC50	0.2	nM	CHEMBL4591963
9.70	IC50	0.2	nM	CHEMBL5885074
9.70	IC50	0.2	nM	CHEMBL5960615
9.70	IC50	0.2	nM	CHEMBL5843321
9.70	IC50	0.2	nM	CHEMBL5928809
9.70	IC50	0.2	nM	CHEMBL5787107
9.70	IC50	0.2	nM	CHEMBL5956303
9.70	IC50	0.2	nM	CHEMBL5818081
9.70	IC50	0.2	nM	CHEMBL4566038
9.70	IC50	0.2	nM	CHEMBL6029645

PubChem BioAssay actives

49 with measured affinity, of 92 total; 49 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-(2-ethylphenyl)-3,5-dimethyl-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.0013	uM
3,5-dimethyl-1-(2-methylphenyl)-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.0015	uM
1-(2-bromophenyl)-5-methyl-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.0023	uM
N-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0035	uM
2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-N-(thiophen-2-ylmethyl)acetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0036	uM
5-methyl-1-(2-methylphenyl)-N-quinolin-2-yltriazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.0041	uM
8-[3-chloro-5-[4-(1-methylpyrazol-4-yl)phenyl]-4-pyridinyl]-2,8-diazaspiro[4.5]decan-1-one	1198342: Inhibition of ligand-induced WNT3A signaling in human PA-1 cells harboring TCF preincubated for 6 hrs before ligand addition measured after 24 hrs by luciferase reporter assay	ic50	0.0070	uM
N-(cyclopropylmethyl)-2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0170	uM
2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-(2-methylpropyl)-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0170	uM
1-(2-bromophenyl)-3,5-dimethyl-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.0210	uM
2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-N-propylacetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0340	uM
2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0400	uM
3,5-dimethyl-1-(2-propan-2-ylphenyl)-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.0480	uM
1-(2-bromo-6-fluorophenyl)-3,5-dimethyl-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.0500	uM
2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-N-(pyridin-2-ylmethyl)acetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0520	uM
N-benzyl-2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0650	uM
N-ethyl-2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0700	uM
2-[4-(trifluoromethyl)phenyl]-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.0780	uM
1-(2-fluorophenyl)-3,5-dimethyl-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.0870	uM
1-(2,5-dimethylphenyl)-3,5-dimethyl-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.0960	uM
3,5-dimethyl-1-phenyl-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.1350	uM
2-[4-(4-fluorobenzoyl)piperidin-1-yl]-N-methyl-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.1930	uM
3-(2-fluorophenyl)-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-N-(thiophen-2-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.3040	uM
1-(2-chlorophenyl)-3,5-dimethyl-N-quinolin-2-ylpyrazole-4-carboxamide	1862157: Inhibition of recombinant human Wnt3a in HEK293 cells assessed as Wnt signalling by measuring reduction in relative luminescence units incubated for 24 hrs by luciferase reporter assay	ic50	0.3050	uM
3-(4-fluorophenyl)-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-N-(thiophen-2-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.4830	uM
3-(3-hydroxyphenyl)-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-N-(thiophen-2-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.8120	uM
N-[(4-oxo-3H-quinazolin-2-yl)methyl]-3-phenyl-N-(thiophen-2-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	0.9370	uM
2-[4-(2-hydroxypropan-2-yl)phenyl]-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	1.0300	uM
4-chloro-5-cyano-N-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-methoxybenzamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	1.1000	uM
2-[4-(trifluoromethoxy)phenyl]-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	1.2200	uM
3-(4-hydroxyphenyl)-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-N-(thiophen-2-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	1.3500	uM
2-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	1.4100	uM
2-[4-(trifluoromethyl)phenyl]-3H-quinazolin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	1.6700	uM
2-[4-(trifluoromethyl)phenyl]-3,6,7,8-tetrahydrothiopyrano[3,2-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	1.7200	uM
N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-3-phenyl-N-(thiophen-2-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	1.9200	uM
2-[4-(trifluoromethyl)phenyl]-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	2.6500	uM
methyl 4-(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)benzoate	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	3.0000	uM
3-(2-hydroxyphenyl)-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-N-(thiophen-2-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	3.7700	uM
2-(4-bromophenyl)-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	4.1400	uM
2-[4-(dimethylamino)phenyl]-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	4.2100	uM
2-(4-chlorophenyl)-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	4.4300	uM
2-(4-methylphenyl)-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	4.6300	uM
2-[4-(trifluoromethyl)phenyl]-4a,5,7,7a-tetrahydro-3H-thieno[3,4-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	5.0400	uM
2-(4-methoxyphenyl)-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	5.0500	uM
2-(4-methylsulfonylphenyl)-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	6.2900	uM
3-(3-fluorophenyl)-N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-N-(thiophen-2-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	6.6100	uM
2-thiophen-3-yl-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-4-one	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	8.0900	uM
N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-3-pyridin-4-yl-N-(thiophen-2-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	8.2500	uM
N-[(4-oxo-3,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]-3-phenyl-N-(thiophen-3-ylmethyl)propanamide	768543: Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin	ic50	8.5400	uM

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Niclosamide	affects localization, decreases reaction, increases stability, decreases expression	3
Chir 99021	affects cotreatment, decreases expression, increases expression, increases reaction, affects binding	2
XAV939	decreases expression, increases expression, decreases reaction, affects binding, affects cotreatment	2
Cadmium	decreases expression, decreases reaction, increases abundance	2
Silicon Dioxide	decreases expression	2
abemaciclib	decreases expression	1
ETC-159	decreases expression	1
aminomethylphosphonic acid (AMPA)	decreases expression	1
thymoquinone	decreases expression	1
baicalein	decreases expression, decreases reaction	1
bisphenol A	affects expression	1
ethyl-p-hydroxybenzoate	increases expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
cypermethrin	increases expression	1
cyfluthrin	increases expression	1
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	decreases reaction, increases expression	1
taraxasterol	increases expression, decreases reaction	1
deguelin	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, increases reaction, affects cotreatment	1
bavachin	increases expression, decreases reaction	1
belinostat	increases expression	1
(+)-JQ1 compound	decreases expression	1
FV-429 compound	affects cotreatment, decreases reaction, increases expression	1
5-furan-2yl-isoxazole-3-carboxylic acid (3-imidazol-1yl-propyl)-amide	affects expression, affects reaction	1
LGK974	decreases expression	1
Telmisartan	decreases expression, decreases reaction	1
Microplastics	increases abundance, increases expression	1
Matrines	decreases expression	1
Glyphosate	increases expression	1
Ethanol	affects cotreatment, increases activity	1

ChEMBL screening assays

31 unique, capped per target: 31 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1267283	Binding	Inhibition of palmitoylation of Wnt3A expressed in mouse L cell by detergent solubility fractionation assessed as [3H]palmitate incorporation at 2.5 uM by autoradiography method	Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. — Nat Chem Biol

Cellosaurus cell lines

8 cell lines: 3 embryonic stem cell, 3 cancer cell line, 1 transformed cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A7V7	SEES3-1V human WNT3A, clone1	Embryonic stem cell	Male
CVCL_A7V8	SEES3-1V human WNT3A, clone2	Embryonic stem cell	Male
CVCL_A7V9	SEES3-1V human WNT3A, clone3	Embryonic stem cell	Male
CVCL_B8RU	Abcam HCT 116 WNT3A KO	Cancer cell line	Male
CVCL_B9U8	Abcam A-549 WNT3A KO	Cancer cell line	Male
CVCL_D8Y9	Ubigene HCT 116 WNT3A KO	Cancer cell line	Male
CVCL_D9VT	Ubigene HEK293 WNT3A KO	Transformed cell line	Female
CVCL_E6SE	Genomeditech CHO-K1 H_WNT3A	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.